250 Million EUR Research Programme on Neurodegeneration Featured at Alzheimer Europe Conference
24 October 2019 - 25 October 2019
The Hague, Netherlands
In recent years, European research projects have brought many crucial stakeholders together. Four Neuronet sessions, as part of the Alzheimer Europe Conference, will provide insights from research projects that have been launched by the Innovative Medicines Initiative (IMI), Europe's biggest public-private partnership in the life sciences.
The Neuronet sessions will introduce the IMI and its neurodegeneration portfolio. The programme is listed below:
Thursday, 24 October, 10.30-12.00
Parallel session P5. European research collaboration in Alzheimer's disease and beyond
The Innovative Medicines Initiative and its neurodegeneration portfolio
Neuronet – Efficiently Networking European Neurodegeneration Research
Patient and Public Involvement in the IMI research portfolio
Thursday, 24 October, 14.00-15.30
Parallel session P13. From risk to dementia – Understanding disease progression and its causes
ADAPTED – Alzheimer's disease apolipoprotein pathology for treatment elucidation and development
PHAGO – Targeting TREM2 and CD33 of phagocytes for treatment of Alzheimer's disease
AETIONOMY – Disease Mechanisms for Patient Subgroup Identification and Disease Progression Modeling
Friday, 25 October, 10.30-12.00
Parallel session P21. Improving data access and the development of predictive models
EQIPD – Data quality in preclinical research
EMIF – European Medical Information Framework
ROADMAP – Real world outcomes across the AD spectrum
IM2PACT – Discovery of blood-brain barrier targets and transport pathways to treat neuro/metabolic diseases – A public-private partnership
Friday, 25 October, 14.00-15.30
Parallel session P29. Diagnosis, patient engagement and trials
AMYPAD – Amyloid imaging to prevent Alzheimer's disease
EPAD – European prevention of Alzheimer's dementia consortium
MOPEAD – Models of Patient Engagement in Alzheimer's Disease: a European project to develop and test innovative patient engagement strategies
RADAR-AD – Remote Assessment of functional decline in Alzheimer's Disease
For more information visit: https://www.imi-neuronet.org/2019-event-the-hague/
The Neuronet sessions will introduce the IMI and its neurodegeneration portfolio. The programme is listed below:
Thursday, 24 October, 10.30-12.00
Parallel session P5. European research collaboration in Alzheimer's disease and beyond
The Innovative Medicines Initiative and its neurodegeneration portfolio
Neuronet – Efficiently Networking European Neurodegeneration Research
Patient and Public Involvement in the IMI research portfolio
Thursday, 24 October, 14.00-15.30
Parallel session P13. From risk to dementia – Understanding disease progression and its causes
ADAPTED – Alzheimer's disease apolipoprotein pathology for treatment elucidation and development
PHAGO – Targeting TREM2 and CD33 of phagocytes for treatment of Alzheimer's disease
AETIONOMY – Disease Mechanisms for Patient Subgroup Identification and Disease Progression Modeling
Friday, 25 October, 10.30-12.00
Parallel session P21. Improving data access and the development of predictive models
EQIPD – Data quality in preclinical research
EMIF – European Medical Information Framework
ROADMAP – Real world outcomes across the AD spectrum
IM2PACT – Discovery of blood-brain barrier targets and transport pathways to treat neuro/metabolic diseases – A public-private partnership
Friday, 25 October, 14.00-15.30
Parallel session P29. Diagnosis, patient engagement and trials
AMYPAD – Amyloid imaging to prevent Alzheimer's disease
EPAD – European prevention of Alzheimer's dementia consortium
MOPEAD – Models of Patient Engagement in Alzheimer's Disease: a European project to develop and test innovative patient engagement strategies
RADAR-AD – Remote Assessment of functional decline in Alzheimer's Disease
For more information visit: https://www.imi-neuronet.org/2019-event-the-hague/
Keywords
Neurodegeneration, Research, Public-private collaboration, Dementia, Alzheimer